Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ravi, Kurukulasuriya"'
Autor:
David A. Candito, Vladimir Simov, Anmol Gulati, Solomon Kattar, Ryan W. Chau, Blair T. Lapointe, Joey L. Methot, Duane E. DeMong, Thomas H. Graham, Ravi Kurukulasuriya, Mitchell H. Keylor, Ling Tong, Gregori J. Morriello, John J. Acton, Barbara Pio, Weiguo Liu, Jack D. Scott, Michael J. Ardolino, Theodore A. Martinot, Matthew L. Maddess, Xin Yan, Hakan Gunaydin, Rachel L. Palte, Spencer E. McMinn, Lisa Nogle, Hongshi Yu, Ellen C. Minnihan, Charles A. Lesburg, Ping Liu, Jing Su, Laxminarayan G. Hegde, Lily Y. Moy, Janice D. Woodhouse, Robert Faltus, Tina Xiong, Paul Ciaccio, Jennifer A. Piesvaux, Karin M. Otte, Matthew E. Kennedy, David Jonathan Bennett, Erin F. DiMauro, Matthew J. Fell, Santhosh Neelamkavil, Harold B. Wood, Peter H. Fuller, J. Michael Ellis
Publikováno v:
Journal of Medicinal Chemistry. 65:16801-16817
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
Autor:
Blair T. Lapointe, Jack D. Scott, Xin Cindy Yan, Haiqun Tang, Janice D Woodhouse, Kaleen Konrad Childers, Robert Faltus, Erin F. DiMauro, Solomon Kattar, Charles S. Yeung, Ravi Kurukulasuriya, Vladimir Simov, Hakan Gunaydin, Anmol Gulati, Joey L. Methot, Rachel L. Palte, Ellen C. Minnihan, Greg Morriello, J. Michael Ellis, Harold B. Wood, Santhosh Neelamkavil, Karin M. Otte, Michael J. Ardolino, Barbara Pio, Ping Liu, Laxminarayan G Hegde, Matthew J. Fell, Vanessa L. Rada, Peter Fuller, Paul J Ciaccio
Publikováno v:
RSC Med Chem
The discovery of potent, kinome selective, brain penetrant LRRK2 inhibitors is the focus of extensive research seeking new, disease-modifying treatments for Parkinson's disease (PD). Herein, we describe the discovery and evolution of a picolinamide-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8d45ea7dd7adda70471298a4476afa
https://europepmc.org/articles/PMC8292993/
https://europepmc.org/articles/PMC8292993/
Autor:
Theodore A. Martinot, Xavier Fradera, Meredeth A. McGowan, Wensheng Yu, Heidi Ferguson, Purakattle J Biju, H. Zhou, Nicolas Solban, Qinglin Pu, Yongxin Han, Xiao Wang, Kun Liu, Ravi Kurukulasuriya, Yu-hong Lam, Abdelghani Achab, Karin M. Otte, Michael J. Ardolino, Amy C. Doty, Charles A. Lesburg, J. Richard Miller, Yongqi Deng, Mangeng Cheng, Hongjun Zhang, Ian Knemeyer, Nunzio Sciammetta, David Jonathan Bennett
Publikováno v:
ACS Med Chem Lett
[Image: see text] Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these break
Autor:
Jinchu Liu, Maarten Hoek, Qiang Tan, Andreas Verras, Don Gauthier, Tim Cernak, Kevin D. Dykstra, Anthony Ogawa, Yun-Fang Yang, Shane W. Krska, Robert J. DeVita, Dong-Ming Shen, Beata Zamlynny, Thomas Bateman, Ravi Kurukulasuriya, Yili Chen, Lisa DiMichelle, Kun Liu, Alejandro Crespo, Petr Vachal, Jeffrey Madwed, Kendall N. Houk
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(14)
The derivatization of pharmaceuticals is a core activity in the discovery and development of new medicines. Late-stage functionalization via modern C H functionalization chemistry has emerged as a powerful technique with which to diversify advanced p
Autor:
Dann L. Parker, Randal M. Bugianesi, Birgit T. Priest, Feroze Ujjainwalla, Edward C. Sherer, Stanley Mitelman, Sharon Tong, Matthew Lombardo, William K. Hagmann, Ravi P. Nargund, Melissa Costa, Christopher Joseph Sinz, Anka G. Ehrhardt, Scott D. Edmondson, Ravi Kurukulasuriya, Xiaofang Li, Karen H. Dingley, Kate Bender, Kevin S. Ratliff, Jonathan E. Wilson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:2947-2951
A novel series of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists are described. The series was designed to address the suboptimal PK (pharmacokinetic) and off-target profile of a class of N-aryl-benzo-[1,4]-oxazepine-4-carboxamides, represent
Autor:
Vincent J. Colandrea, Ravi Kurukulasuriya, Petr Vachal, Beth Ann Murphy, Rajan Anand, Kake Zhao, Mikhail Reibarkh, Alejandro Crespo, Ruth A. Duffy, Joseph L. Duffy, Jonathan E. Wilson, Anne-Marie Cumiskey, Maud Reiter, Aaron Zwicker, Fengqi Zhang, Kaushik Mitra, Douglas G. Johns
Using the collective body of known (CETP) inhibitors as inspiration for design, a structurally novel series of tetrahydroquinoxaline CETP inhibitors were discovered. An exemplar from this series, compound 5, displayed potent in vitro CETP inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f1f63cab482d2b7431e81a19537bcf
https://europepmc.org/articles/PMC4789658/
https://europepmc.org/articles/PMC4789658/
Publikováno v:
Current Topics in Medicinal Chemistry. 7:569-578
Xanthines and xanthine-like DPP-IV inhibitors were first disclosed in 2002. Since then, several dozen accounts of xanthine-based DPP-IV inhibitors have been published. Only a few presentations and journal articles have appeared, with the vast majorit
Autor:
Jiahong Wang, DeAnne Stolarik, Hovis M. Imade, Victoria Knourek-Segel, Phong Nguyen, Denise Wilcox, Peer B. Jacobson, Michael E. Brune, William Chiou, Steven Fung, Robin Shapiro, Vince Yeh, J.T. Link, Ravi Kurukulasuriya, Katina Monzon, Eugene N. Bush
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:5555-5560
A series of metabolically stable butyrolactam 11beta-HSD1 inhibitors have been synthesized and biologically evaluated. These compounds exhibit excellent HSD1 potency and HSD2 selectivity, pharmacokinetic, and pharmacodynamic profiles.
Autor:
William J. Chiou, Jiahong Wang, Jyoti R. Patel, Peer B. Jacobson, Michael E. Brune, J.T. Link, Ravi Kurukulasuriya, Hong Yong, Hing L. Sham, Steven Fung, Katina Monzon, DeAnne Stolarik, Hovis M. Imade, David W A Beno, Vince Yeh
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:5414-5419
A series of metabolically stable adamantane amide 11beta-HSD1 inhibitors have been synthesized and biologically evaluated. These compounds exhibit excellent HSD1 potency and HSD2 selectivity and good pharmacokinetic and pharmacodynamic profiles.
Autor:
J.T. Link, Ravi Kurukulasuriya
Publikováno v:
Expert Opinion on Therapeutic Patents. 15:1739-1749
Peptidal glucagon receptor antagonists and antiglucagon monoclonal antibodies lower glucose levels in diabetic rodent models, suggesting a potential to treat hyperglycaemia in Type 2 diabetics through the inhibition of glucagon function. Several rese